NeuroPace (NPCE) said late Monday that it expects "minimal impact" to its operations and financial results from the Trump administration's tariffs .
The medical device company said it manufactures and sells the "vast majority" of its devices in the US and has "limited" supply chain activities outside the country for its responsive neurostimulation System.
The firm expects "no material" impact on gross margin for DIXI Medical SEEG products.
It expects "minimal impact" to gross margin for fiscal 2025 and is reiterating its gross margin guidance for 2025.
NeuroPace will report Q1 financial results after market close on May 13.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。